8 results on '"Machado, Paulo R. L."'
Search Results
2. A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil.
- Author
-
Machado, Paulo R L, Prates, Fernanda V O, Boaventura, Viviane, Lago, Tainã, Guimarães, Luiz H, Schriefer, Albert, Corte, Temis W F, Penna, Gerson, Barral, Aldina, Barral-Netto, Manoel, and Carvalho, Edgar M
- Subjects
- *
GRANULOCYTE-macrophage colony-stimulating factor , *DRUG efficacy , *LEISHMANIASIS , *CONFIDENCE intervals , *LOG-rank test , *LEISHMANIA , *FISHER exact test , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *T-test (Statistics) , *DESCRIPTIVE statistics , *DATA analysis software - Abstract
Background The treatment of cutaneous leishmaniasis (CL) in Brazil using pentavalent antimony (Sbv) is associated with a high rate of failure. Miltefosine has proven efficacy for CL caused by L. braziliensis, with a cure rate (CR) of 75%. A combined treatment with granulocyte macrophage colony-stimulating factor (GM-CSF) and miltefosine could increase CR and decrease healing time. Methods A randomized, double-blind clinical trial to evaluate the efficacy of miltefosine combined with topical GM-CSF (M + GM) vs miltefosine and placebo (M + P) vs Sbv in 133 patients with CL caused by L. braziliensis in Bahia, Brazil. Results The final CR at 180 days after the initiation of treatment was 44.4% in the Sbv group, 76.6% in the M + P group (P =.003 vs Sbv), and 75.6% in the M + GM group (P =.004 vs Sbv). The median healing time for cure was 102 days for the Sbv group and 60 days for both miltefosine groups (P =.0009). During the 6-month follow-up period, 4 relapses were documented: 1 in the Sbv group, 1 in the M + P group, and 2 in the M + GM group. Mild adverse events occurred in 65% of patients from the Sbv group, 76% and 79% from the M + P and M + GM groups respectively. Conclusions Miltefosine is more effective than Sbv for the treatment of CL caused by L. braziliensis in Brazil and accelerates the healing time. Association with GM-CSF does not improve therapeutic outcome. Clinical Trials Registration NCT03023111. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Diabetes Modifies the Clinic Presentation of Cutaneous Leishmaniasis.
- Author
-
Lago, Alexsandro S, Lima, Filipe R, Carvalho, Augusto M, Sampaio, Camilla, Lago, Neuza, Guimarães, Luiz H, Lago, Jamile, Machado, Paulo R L, Carvalho, Lucas P, Arruda, Sérgio, and Carvalho, Edgar M
- Subjects
CUTANEOUS leishmaniasis ,POLYMERASE chain reaction - Abstract
Background Cutaneous leishmaniasis (CL) caused by L. braziliensis is characterized by 1 or multiple well-limited ulcerated lesions. Diabetes mellitus (DM) impairs neutrophil and monocyte function, and there is a report of vegetative lesions in a patient with both diseases in Morocco. Here we evaluate the influence of DM on clinical manifestations, immune response, and in the treatment of CL. Methods The participants were 36 DM patients with CL and 36 patients with CL without DM, matched by age and gender. The diagnosis of CL was performed by documentation of DNA of L. braziliensis by polymerase chain reaction in the lesion biopsy and histopathologic findings. All patients were treated with Glucantime (Sanofi-Aventis) 20 mg/kg of weight per day for 20 days. Results There was no difference in the majority of the clinical variables between the groups, and the cure rate in patients with CL and DM (67%) was similar to that observed in CL patients (56%; P ˃.05). The most important finding was the documentation that 36% of the patients with DM and CL had atypical cutaneous lesions characterized by large superficial ulcers without defined borders. High levels of interferon-γ, tumor necrosis facor, and interleukin-1β were detected in the supernatants of mononuclear cells stimulated with Leishmania antigen in patients with DM and atypical CL. Moreover, while cure was observed in only 33% of the patients with DM and atypical CL lesions, it was observed in 85% of patients with typical lesions (P < .05). Conclusions DM modifies the clinical presentation of CL, enhances pro-inflammatory cytokine production, and impairs response to antimony therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis: A Randomized Controlled Trial.
- Author
-
de O. Prates, Fernanda V., Dourado, Mayra E. F., Silva, Silvana C., Schriefer, Albert, Guimarães, Luiz H., das Graças O. Brito, Maria, Almeida, Juliana, Carvalho, Edgar M., and Machado, Paulo R. L.
- Subjects
FLUCONAZOLE ,CUTANEOUS leishmaniasis ,LEISHMANIA ,RANDOMIZED controlled trials ,ANTIMONY ,DIZZINESS ,THERAPEUTICS - Abstract
Background. The treatment of cutaneous leishmaniasis (CL) caused by Leishmania braziliensis in Brazil with pentavalent antimony (Sb
v ) is associated with a high rate of failure, up to 45% of cases. In addition, Sbv can only administered parenterally and has important toxic effect. An effective, safe, and oral treatment for CL is required. Methods. A randomized controlled clinical trial was conducted to compare the efficacy and safety of high-dosage oral fluconazole (6.5-8.0 mg/kg/d for 28 days) versus a standard Sbv protocol (20 mg/kg/d for 20 days) for the treatment of CL in Bahia, Brazil. Results. A total of 53 subjects were included in the trial; 26 were treated with Sbv , and 27 with fluconazole. Intention-to-treat analysis showed initial cure rates (2 months after treatment) of 22.2% (6 of 27) in the fluconazole and 53.8% (14 of 26) in the Sbv group (P = .04). Six months after treatment, the final cure rate remained the same in both groups, without any relapses. The frequencies of adverse effects in the Sbv and fluconazole groups were similar, 34.6% versus 37% respectively. One patient treated with fluconazole discontinued treatment owing to malaise, headache, and moderate dizziness (Common Terminology Criteria for Adverse Events grade 2). Conclusions. Oral fluconazole at a dosage of 6.5-8 mg/kg/d for 28 days should not be considered an effective treatment for CL caused by L. braziliensis. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
5. Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B.
- Author
-
Machado, Paulo R. L., Rosa, Maria Elisa A., Guimarães, Luís H., Prates, Fernanda V. O., Queiroz, Adriano, Schriefer, Albert, and Carvalho, Edgar M.
- Subjects
- *
LEISHMANIASIS treatment , *AMPHOTERICIN B , *LIPOSOMES , *LEISHMANIA , *CHEMOKINES , *IMMUNOREGULATION , *ADVERSE health care events , *THERAPEUTICS - Abstract
Background: Disseminated leishmaniasis (DL) is a severe and emerging form of American tegumentary leishmaniasis, associated primarily with infection by Leishmania brasiliensis. DL is defined by the presence of ≥10 mixedtype lesions such as inflammatory papules and ulcers, located in ≥2 body parts. Most patients have hundreds of lesions all over the body, and mucosal involvement is detected in up to 44% of cases. DL is a difficult to cure disease and pentavalent antimony (Sbv) is used as standard treatment, its highest dosage being 20 mg/kg/day, for 30 days. However, less than 25% of DL cases will be cured after standard therapy, and the majority of cases will require more than one course of Sbv for a cure. In this context, new therapies are needed that offer a higher cure rate and a better safety profile, with convenience in drug administration. Methods: We have evaluated liposomal amphotericin B in 20 patients with DL in an open clinical trial. The total dose ranged from 17 to 37 mg/kg, used in 7 to 14 days of treatment. Results: Cure rate at 3 months after therapy was 70%. One relapse was documented 4 months after treatment, producing a final cure rate of 65%. Although liposomal amphotericin B was considered well tolerated, mild adverse events were documented in 75% of the patients. Conclusions: Liposomal amphotericin B is an effective therapy for DL, with a higher final cure rate of 75% observed when used in a total dose above 30 mg/kg. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Intermediate monocytes contribute to pathologic immune response in Leishmania braziliensis infections.
- Author
-
Passos, Sara, Carvalho, Lucas P, Costa, Rúbia S, Campos, Taís M, Novais, Fernanda O, Magalhaes, Andréa, Machado, Paulo R L, Beiting, Daniel, Mosser, David, Carvalho, Edgar M, Scott, Phillip, and Magalhães, Andréa
- Subjects
GLYCOPROTEIN analysis ,CELL receptors ,INFLAMMATORY mediators ,LEISHMANIA ,LEISHMANIASIS ,MONOCYTES ,RESEARCH funding ,TUMOR necrosis factors ,ULCERS - Abstract
Ulcer development in patients with cutaneous leishmaniasis (CL) caused by Leishmania braziliensis is associated with high levels of tumor necrosis factor (TNF). We found that early after infection, before ulcer development, the frequency of CD16(+) (both intermediate [CD14(+)CD16(+)] and nonclassical [CD14(dim)CD16(+)]) monocytes was increased in the peripheral blood of patients with L. braziliensis, compared with uninfected controls. These results suggest that CD16(+) monocytes might promote disease. Also, we found that intermediate monocytes expressed CCR2 and that increased levels of CCL2 protein were present in lesions from patients, suggesting that intermediate monocytes are more likely than nonclassical monocytes to migrate to the lesion site. Finally, we found that the intermediate monocytes produced TNF. Our results show that intermediate monocytes are increased in frequency soon after infection; express CCR2, which would promote their migration into the lesions; and, owing to their production of TNF, can enhance the inflammatory response. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Cutaneous Leishmaniasis during Pregnancy: Exuberant Lesions and Potential Fetal Complications.
- Author
-
Morgan, Daniel J., Guimaraes, Luiz H., Machado, Paulo R. L., D'Oliveira Jr., Argemiro, Almeida, Roque P., Lago, Ednaldo L., Faria, Daniela R., Tafuri, Wagner L., Dutra, Walderez O., and Carvalho, Edgar M.
- Subjects
LEISHMANIASIS ,PREGNANCY complications ,PREGNANT women ,MEDICAL care ,FETAL death - Abstract
Cutaneous leishmaniasis affects millions of people worldwide. After observations of atypical lesions in pregnant women at the health centers of Corte de Pedra, Brazil, 9 years of records were reviewed, and 26 pregnant patients were identified. A retrospective case-control study revealed that lesions in pregnant women were much larger than those in nonpregnant patients in an age- and sex-matched group (mean area, 6.08 cm² vs. 1.46 cm²;P = .008), and many lesions had an exophytic nature. Despite foregoing treatment until after delivery, response to pentavalent antimony therapy was favorable (rate of cure with 1 course of treatment, 85%). High rates of preterm births (10.5%) and stillbirths (10.5%) were reported. Cutaneous leishmaniasis during pregnancy produces distinct lesions and may have adverse fetal effects. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
8. Oral Pentoxifylline Combined with Pentavalent Antimony: A Randomized Trial for Mucosal Leishmaniasis.
- Author
-
Machado, Paulo R. L., Lessa, Hélio, Lessa, Marcus, Guimarães, Luiz H., Heejung Bang, Ho, John L., and Carvalho, Edgar M.
- Subjects
- *
NECROSIS , *ANTI-infective agents , *MUCOUS membranes , *TUMORS , *GLYCOPROTEINS , *TUMOR necrosis factors - Abstract
Background. Mucosal leishmaniasis is associated with intense tissue damage and high tumor necrosis factor-α production. Therapeutic failure occurs in up to 42% of eases; patients who experience treatment failure will require >1 pentavalent antimony (Sbv) course or alternative drugs to achieve a cure. We previously showed that an inhibitor of tumor necrosis factor-α (pentoxifylline) combined with Sbv cured 90% patients refractory to monotherapy with Sbv. Methods. A double-blind, placebo-controlled trial involving 23 patients with mucosal leishmaniasis evaluated the efficacy of pentoxifylline when administered in association with Sbv, compared with Sbv treatment alone. Eleven patients were randomized to receive Sbv plus oral pentoxifylline for 30 days, and 12 patients received Sbv plus oral placebo. The criterion for cure was a complete healing of lesions. Results. All patients in the pentoxifylline group experienced a cure with 1 course of Sbv, whereas 5 (41.6%) of 12 patients in the placebo group required a second course of Sbv (P = .037). The healing time ± standard deviation in the pentoxifylline group was 83 ± 36 days, compared with 145 ± 99 days in the placebo group (P = .049). No relapses were documented in either group at the 2-year follow-up visit. Conclusions. The addition of pentoxifylline to Sbv in mucosal leishmaniasis reduces the healing time significantly and prevents the need for further courses of Sbv. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.